PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This two-day program was attended by 40 doctors & paramedical staff
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Morepen Labs successfully raised Rs. 200 Crore through QIP
Subscribe To Our Newsletter & Stay Updated
